FIGURE 3.

Median plasma concentration over time in part A^a of the study (pharmacokinetic population^b). Median plasma concentrations of GSK3358699 (top) and the metabolite GSK3206944 (bottom) over 48 hours following treatment with a single dose of GSK3358699 (1, 3, 10, 20, 30 or 40 mg) are shown on a linear (left) and semilogarithmic scale (right). SD, single dose. ^aPart A was a single ascending‐dose crossover study in two interlocking cohorts. Each participant received a maximum of two single ascending oral doses of GSK3358699 (1, 3, 10, 20, 40 or 30 mg) and one dose of placebo. ^bThe pharmacokinetic population included all participants who received an active dose of the study drug and for whom pharmacokinetic samples were obtained and analysed